Introduction
Coronary artery disease (CAD) is a main cause of death in large parts of world. Guidelines recommend a non-invasive approach for diagnosing stable CAD, but no unequivocal diagnostic strategy has been established and clinical practise varies substantially. 1, 2 Coronary computed tomography angiography (CCTA) is increasingly used to examine patients with low/intermediate risk of CAD and has replaced treadmill testing in some countries. Despite its excellent sensitivity, CCTA has low positive predictive value (PPV), which often leads to overestimation of the severity of CAD. It is a general concern that the introduction of CCTA has neither substantially reduced the number of invasive coronary angiographies (ICAs) nor increased the frequency of revascularization procedures after ICA. Hence, ICA may continue to be overused in the diagnostic pathway even if most investigated patients do not have obstructive CAD. 3, 4 Because of the low diagnostic yield of CCTA, it has recently been suggested that perfusion techniques or computed fractional flow reserve (FFR) based on CT images be used to avoid unnecessary invasive investigations. 5 Many studies estimating the diagnostic accuracy of cardiac magnetic resonance (CMR) and myocardial perfusion scintigraphy (MPS) have used quantitative coronary analysis (QCA) with ICA as a reference standard. 6, 7 However, QCA is a poor predictor of the functional significance of a coronary stenosis. 8 Furthermore, many perfusion studies have included mainly high-risk patients scheduled for ICA due to symptoms suggestive of CAD. 9 The Dan-NICAD trial was designed to assess the diagnostic accuracy of CMR and MPS as second-line tests in a population with suspected CAD based on CCTA.
Methods Patients and study design
A detailed description of the Dan-NICAD trial design and its inclusion/ exclusion criteria has previously been published. 10 The trial was a two- 
Procedures Coronary computed tomography angiography
CCTA scans were performed with a 320 slice volume CT scanner (Aquillion One, Toshiba Medical Systems, Japan) using prospective electrocardiographic (ECG) gating. The images were analysed on a dedicated workstation (Vitrea Advanced Workstation, Vital Images, USA) by an experienced cardiologist. Luminal diameter stenosis was evaluated in each segment using the 18-segment Society of Cardiovascular Computed Tomography (SCCT) model. 11 Coronary lesions were quantified for stenosis by visual estimation; and severity was classified as no stenosis: 0% diameter reduction; mild stenosis: 1% to 29% diameter reduction; moderate stenosis: 30% to 49% diameter reduction; and severe stenosis: 50% to 100% diameter reduction. Severe stenosis and non-evaluable segments with a diameter exceeding 2 mm were defined as obstructive CAD.
Myocardial perfusion imaging
MPS was obtained using a dedicated gamma camera (Cardio MD, Philips Healthcare, Best, Holland) equipped with LEHR collimators and Vantage TM Gadolinium-153 line sources. Patients conducted a standard symptom-limited exercise test on a bicycle (25 W/2 min). Beta-blocker treatment was withdrawn 48 h before exercise testing. An increase of at least 85% of maximum heart rate (HR, 220-age) was considered sufficient. If patients were unable to reach target HR, adenosine stress was performed. If stress images revealed any perfusion or motion abnormality, a standard resting image protocol was obtained.
Images were analysed using Cedar Sinai AutoQuant software by an independent core lab (Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, Denmark) blinded of patient information. MPS images were assessed using a 17-segment model. For each segment, perfusion defects were assessed automatically and adjusted visually using a 5-point scoring system (0: normal and up to 4: absence of tracer uptake). Scores from stress and rest images were summed; and a summed stress score (SSS), summed rest score (SRS), and a summed difference score (SDS) generated. Images were evaluated qualitatively with a binary outcome (normal/abnormal). An abnormal MPS scan was defined as (i) an SDS > _ 4 involving > _ 2 contiguous segments (reversible defect), (ii) an SRS > _ 4 involving > _ 2 contiguous segments (irreversible defect), and (iii) a combination of (i) and (iii) (mixed defect). Analysis at vessel level was performed so that each segment was assigned to a vessel. Left 
Cardiac magnetic resonance imaging
The CMR scans were conducted using a 1.5 Ta system (Siemens MAGNETOM Avanto, Siemens Healthcare GmbH, Erlangen, Germany) with a 32-channel cardiac coil. Stress perfusion imaging was conducted after intravenous injection of either 0.4 mg (5 ml) of Regadenosone V R (Lexiscan, Astellas Pharma, USA) or intravenous adenosine-induced hyperaemia 140 lg/kg/min over 4 min. A stepwise increase in adenosine dose was administered in case of inadequate response. For adenosine stress an increase of >10 bpm or a blood pressure reduction >10 mmHg from baseline was considered sufficient. 12 For Regadenosone V R an increase in HR of >10 bpm was considered a sufficient clinical response. Splenic switch-off was registered in all patients stressed with adenosine. As contrast agent, either Gadovist V R (Bayer Schering Pharma AG, Germany) or Dotarem
(GD-DOTA, Guerbet LCC, USA), was used. CMR analysis was performed in an independent core lab (William Harvey Research Institute, Queen Mary University of London, London, UK) blinded from additional patient information and results. Diagnostic confidence was evaluated using a scale from 1-3, indicating high, medium, or low image quality. Images were evaluated qualitatively with a binary outcome (normal/abnormal) based on the perfusion analysis. Significant perfusion defects were defined as subendocardial or transmural signal changes by stress imaging or irreversible defects in > _2 contiguous segments by late gadolinium enhancement (LGE) imaging. Analysis at vessel level was performed as for the MPS examinations with each segment assigned to a vessel.
Prior knowledge image analysis
A pre-specified prior knowledge image analysis was performed after the blinded core-lab analysis to mimic normal clinical practice. Clinical information regarding symptoms, medicine, and risk factors as well as the results from the CCTA scan was revealed to the same core labs and the CMR/MPS reanalysed. The readers remained blinded to the result of the ICA.
Invasive coronary angiography with fractional flow reserve ICA was performed approximately 4 weeks after CCTA. FFR measurements (St. Jude Medical, MN, USA and Volcano, San Diego, CA, USA) were performed if technically possible in all coronary segments with a diameter > 2 mm where ICA showed a stenosis with a diameter > _ 30 and <90% by visual assessment. Hyperaemia during FFR measurements was induced with I.V. adenosine. A plateau-phase of the FFR value was secured after 30-90 s; however, if this was not achieved, the adenosine dose was increased. It was routinely checked that drift did not occur, after all recordings a subsequent measure of the FFR-value at the aorta site was conducted. If the value exceeded 1.04 or was below 0.96, the FFR-measurement was repeated.
All pressure waveforms were analysed by a core lab (Interventional Coronary Imaging Core Laboratory, Aarhus University Hospital, Denmark). Two-dimensional (2D) QCA was performed in an independent core lab (ClinFact, Leiden, The Netherlands) using QAngioXA 7.3 QCA software.
Haemodynamic significant CAD was defined as FFR < _ 0.80, or as high-grade stenosis (>90% diameter stenosis) by visual assessment during the ICA in a vessel with a reference diameter above > _2.0 mm. If FFR was not technically possible, a QCA-measured stenosis exceeding > _50% diameter stenosis indicated significant stenosis.
Statistical analysis
Data analysis and reporting follow the Standards for Reporting of Diagnostic Accuracy (STARD) guidelines and the Consolidated Standards of Reporting Trials (CONSORT). Continuous variables were expressed using mean (±SD) and categorical variables as n (%). Based on previous data, we assumed a prevalence of CAD in 50% of patients referred to further investigations after CCTA and a sensitivity and specificity of 0.83 for both MPS and CMR. Based on these assumptions, a final randomized study cohort of 300 patients is required for a minimum of 10% absolute precision on both sides [half width of the confidence interval (CI)] of the expected sensitivity and specificity. Independence between study arms are assumed as randomization has been conducted 1:1 without stratification and independently from the research staff. Diagnostic performance and sub-analyses were evaluated on both patient and vessel level by sensitivity, specificity, predictive values, and likelihood ratios, and results are presented with 95% CIs. For all statistical analysis, 95% CI is reported when appropriate; and if CIs did not overlap, significance was not reported. Statistical analyses were performed as per-patient protocol and drop-outs were handled as missing data. Statistical analysis was performed using STATA-13 (StataCorp, College Station, TX, USA).
Results

Patient population
In total, 2087 patients with low-intermediate pre-test probability of CAD were asked to participate in the study, Figure 1 and Table 1 . Patients were recruited from 11 September 2014 until 31 March 2016. In the Supplementary data online, information regarding the intention-to-treat and per-patient protocol population is presented. A total of 412 patients declined to participate, the mean age in this group was 57.9 ± 10.1 years and 271 were female (66%). Of the 1675 participants, 392 (23.4%) had suspected CAD on CCTA and were randomized to CMR (197) or MPS (195). Complete ICA data were available for 362 patients and both CMR and ICA were completed in 148 (75%) patients and MPS and ICA were completed in 144 (73.8%) patients. Patients with complete data were included in the analyses.
One hundred patients did not complete the full study protocol, 22 (22%) left the study and had their further examinations and treatment transferred to other hospitals. Seventy completed only ICA, and 8 patients completed only perfusion scanning. Disease prevalence was 43/70 (61%) in the group completing only ICA, indicating that these patients had a larger disease burden. See Figure 1 for details. Perfusion defects by CMR were present in 38 patients; 27/38 (71%) had reversible ischaemia, 10/38 (26%) had mixed irreversible and reversible ischaemia and 1/38 (3%) had image quality to poor for evaluation. Perfusion defects by MPS were present in 27 patients; 19/27 (70%) had reversible ischaemia, 6/27 (22%) had mixed irreversible, and reversible ischaemia and 2/27 (8%) had irreversible ischaemia.
FFR was indicated in 191 patients and measured in 167 patients (87%) and indicated in 250 vessels and measured in 225 (90%). Mean FFR was 0.83 ± 0.09.
Diagnostic accuracy: patient level
The main results of the comparison between MPS and CMR to detect significant CAD by ICA are presented in Figure 2a and b. Performance did not differ between CMR and MPS at patient level.
Results from the prior knowledge approach at patient level are also presented in Figure 2a and b.
We observed no significant difference between the prior knowledge analyses of CMR and MPS and no significant difference between CMR and prior knowledge CMR or MPS and prior knowledge MPS.
Patient examples for MPS and CMR examinations are presented in
Figures 3 and 4.
Diagnostic accuracy: vessel level
Disease was classified in 70/452 (15.5%) vessels by CMR and in 57/ 435 (13.1%) vessels by MPS. Results are presented in Figure 5a and b. No statistically significant difference was found between MPS and CMR compared to haemodynamic disease by ICA at vessel level.
Disease was classified by prior knowledge CMR in 69/452 (15.3%) vessels and by prior knowledge MPS in 57/435 (13.1%) vessels. Results are presented in Figure 5a and b. We observed a statistically significant difference in the specificity between CMR and prior 
Sub-analyses
We performed sub-analyses for CMR and MPS at patient level compared separately to FFR < _ 0.80, QCA > _ 50% diameter stenosis, and >90% diameter stenosis. The results for these data are presented in Figure 6 .
Discussion
The results of the Dan-NICAD trial demonstrated that MPS and CMR, as second-line examinations after CCTA, had similar low sensitivities (30-41%) and high specificities (84-93%) compared to ICA-FFR. Importantly, all eligible patients within a geographical area were asked to participate after referral to CCTA. As 99% of hospital care 
Figure 6
Sub-analyses with FFR < _ 0.80, QCA > _ 50% diameter stenosis, and >90% diameter stenosis as a reference standard. Sub-analyses were performed using different end points. In the FFR analysis, disease was defined as FFR < _ 0.80. Only the 167 patients (89 CMR, 78 MPS) in whom FFR was measured participated in this analysis. In the QCA analysis, disease was defined as QCA > _ 0.50, and all 292 patients (148 CMR, 144 MPS) were evaluated with QCA. In the visual assessment analysis, >90% diameter stenosis was defined as disease; only 57 patients (30 CMR, 27 MPS) had a highgrade stenosis and were included in this analysis. FFR, fractional flow reserve; QCA, quantitative coronary angiography; CMR, cardiac magnetic resonance; MPS, myocardial perfusion scintigraphy; ICA, invasive coronary angiography.
Diagnosing coronary artery disease after a positive coronary computed tomography angiography in Denmark is public, few alternative options were available to patients beyond the two recruiting centres; we therefore consider this population as representative and the results generalizable.
In Denmark treadmill testing, Dobutamine V R stress echocardiography and MPS are rarely used for screening in patients with low/intermediate probability of CAD and in line with the recent NICE recommendations 1 CCTA is the preferred method for screening.
In the Dan-NICAD trial, we performed MPS examinations using Technetium-SPECT technique and CMR examinations with a 1.5 T MR scanner as this reflects clinical practice in most of the world. We also used local standard clinical protocols for the perfusion scans to reflect present clinical practice.
The sensitivity and specificity of the different imaging modalities, MPS and CMR, have been addressed in several publications. 7, 9, 13, 14 Previous studies recruited patients based on symptoms, positive treadmill test, or invasive findings and most frequently compared with QCA. General sensitivities in the 70-85% range have been documented against ICA with QCA for MPS and slightly higher sensitivities have been reported for CMR.
7,9 CE-MARC is the largest prospective trial assessment of CMR and MPS using QCA as a reference standard, reporting sensitivities for CMR/MPS of 86.5/66.5% and specificities of 83.4/82.6%. 7 The MARCC study evaluated a set-up using a combined approach with CCTA and CMR using ICA with FFR as a reference standard in cases with either a positive CCTA and/or a positive CMR, 15 both sensitivity and specificity were high, 85% and 94%, respectively. A recent meta-analysis 16 finds that only four CMR studies are performed measuring FFR in more than 75% of the enrolled study population and all studies are performed in selected and skilled centres, which indicates the need for studies conducted in routine clinical practice. In the present study, patients undergoing perfusion imaging were selected based on the CCTA findings, and the reference standard was ICA with conditional FFR measurements. The disease prevalence in the randomized part of the Dan-NICAD population was 40%, which is similar to the disease prevalence of 39% in the CE-MARC study, even if the two studies are not directly comparable due to different use of reference standards. 7 As MPS and CMR performed similarly and the patients were adequately stressed according to common clinical practice, the discrepancy in sensitivity between other studies and the Dan-NICAD study may be due either to the patient population or the chosen reference standard, which represents a conceptually different approach to reflect myocardial ischaemia. Compared to patients selected based on clinical symptoms or a positive treadmill test, patients in the Dan-NICAD trial was selected using CCTA and therefore might have more localized disease which may cause smaller areas of ischaemia and increase the risk of underdiagnosing a possible perfusion abnormality.
As a reference standard for haemodynamic disease, we used ICA with conditional FFR, which is considered the gold standard. 17 In one of the first FFR validation studies, the average FFR values were around 0.60, 18 as opposed to the higher mean FFR in this study (0.83).
Consequently, many patients have lesions close to the discrimination value of 0.8 and small changes or inaccuracies in measurements would switch the patients from FFR positive to negative and vice versa. 19 Although FFR has proven prognostic impact, 17 it remains a surrogate measure of coronary flow reduction and has documented limitations in predicting the specific coronary flow reduction for a stenosis and, moreover, in indirectly detecting myocardial ischaemia. 20 Pressure drop across a coronary stenosis is determined by the magnitude of coronary flow, so a pressure drop increases with an increase in baseline coronary flow and decreases with decreasing flow. A high coronary flow can therefore coexist with an abnormal FFR value, and such discordance between FFR and measurements of flow often occurs, which illustrates that FFR is not always a reliable estimate of coronary flow impairment. [21] [22] [23] Despite the low sensitivity observed in our study, an imaging based strategy could be regarded as safe in terms of prognosis. The PROMISE trial has shown no difference in outcome between symptomatic patients initially tested with either CCTA or a perfusion sca. 24 Also the CE-MARC 2 study has shown that an imaging based strategy with either CMR or MPS is superior to the NICE guidelines in terms of avoiding unnecessary ICAs not leading to revascularization. 25 Patient outcome is what is important for the patient and both CE-MARC 2 and the PROMISE trial showed that a perfusion based strategy leads to fewer angiographies and revascularization without impairing patient outcome. Future studies should be performed to determine which technique will best select patients who will benefit from revascularization in terms of symptoms and prognosis.
The DEFINE FLOW (NCT02328820) is currently testing the combination of FFR and CFR to guide treatment of coronary stenosis. Results from this and other studies quantifying flow using perfusion imaging will help clarify the discrepancy observed between invasive and non-invasive techniques.
Limitations
Although identical scanners were used in our two-centre study, the scan protocols were not completely unified for all patients. The CMR scans were performed using different pharmacological stress; adenosine or Regadenosone V R and different contrast agents. Performance variables did not differ between the two centres. We performed MPS examinations using mainly exercise stress, and if this was not possible pharmacological stress was induced with adenosine. Usual clinical criteria for a sufficient response were used in all patients. We specifically chose this setup to reflect normal clinical practice when examining intermediate-risk patients. As outlined in the CONSORT flowchart we had approximately 25% missing data among perfusion scans, this was within the expected range according to the protocol 10 and there was no difference in drop-outs between the two randomization arms. Finally, almost all participants were Caucasians with no previously diagnosed CAD, and results might differ in other populations and health care systems.
Conclusion
In patients with suspected angina, we found low sensitivity for both CMR and MPS used as second-line perfusion investigations after a CCTA scan identified CAD. We also found that there was no significant difference between CMR and MPS as second-line perfusion
